C1QTNF3-AMACR: A Potential Drug Target and Biomarker (G100534612)

Target Name: C1QTNF3-AMACR

NCBI ID: G100534612

C1QTNF3-AMACR

Other Name(s): C1QTNF3-AMACR readthrough (NMD candidate)

C1QTNF3-AMACR: A Potential Drug Target and Biomarker

C1QTNF3-AMACR, also known as CSF-1, is a protein that is expressed in various tissues, including the brain, and plays a crucial role in the regulation of cell signaling pathways. The analysis of CSF-1 has been ongoing for several years, and its potential as a drug target or biomarker has been gaining attention. In this article, we will discuss the potential of C1QTNF3-AMACR as a drug target and biomarker, and its current status in the scientific community.

Potential Drug Target

C1QTNF3-AMACR has been identified as a potential drug target due to its unique structure and its involvement in various signaling pathways. C1QTNF3-AMACR is a transmembrane protein that is composed of four domains: an extracellular domain, a transmembrane domain, an intracellular domain, and a C-terminal domain. It has a unique feature, a N-terminal hypervariable region (HVR), which is composed of 21 amino acids.

The N-terminal HVR is important for protein-protein interactions and has been implicated in various signaling pathways. C1QTNF3-AMACR has been shown to interact with several proteins, including the transcription factor, NF-kappa-B, and the protein kinase, MAPK. These interactions may play a role in the regulation of various cellular processes, including cell signaling pathways, inflammation, and neurodegeneration.

C1QTNF3-AMACR has also been shown to be involved in the regulation of cellular stress responses. It has been shown to interact with the protein, heat shock protein (HSP70), and to play a role in the regulation of cellular stress responses.

Potential Biomarker

C1QTNF3-AMACR has also been identified as a potential biomarker for various diseases, including neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These diseases are characterized by the progressive loss of brain cells and the development of various cognitive impairments.

Studies have shown that the expression of C1QTNF3-AMACR is altered in neurodegenerative diseases. For example, research has shown that the expression of C1QTNF3-AMACR is decreased in the brains of individuals with Alzheimer's disease. Additionally, C1QTNF3-AMACR has been shown to be involved in the regulation of neurotransmitter release, which is a crucial aspect of neurodegenerative diseases.

Conclusion

In conclusion, C1QTNF3-AMACR is a protein that has the potential to be a drug target and a biomarker. Its unique structure and its involvement in various signaling pathways make it an attractive target for drug development. Further research is needed to fully understand the role of C1QTNF3-AMACR in the regulation of cellular processes and to determine its potential as a drug and biomarker.

Protein Name: C1QTNF3-AMACR Readthrough (NMD Candidate)

The "C1QTNF3-AMACR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C1QTNF3-AMACR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets